Moderna: Invest Now Or Never?

Moderna, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, that develops new drugs, vaccines, and other medicines using new technologies based on messenger RNA. The company's success with its coronavirus vaccine has led to a surge in its stock price since 2019, and it is now generating billions of dollars in revenue. However, there are some concerns about the future of the company's COVID-19 vaccine sales as demand plunges and the pandemic transitions to an endemic. Moderna has responded by developing a 10-year subscription program and raising the price of its vaccine for private buyers. The company is also expanding its efforts in cancer treatment and developing a combination vaccine to prevent COVID-19 and the flu. While Moderna stock is not currently considered a buy, some analysts believe that now may be a good time to invest due to the company's reduced risk, strong earnings, and advanced pipeline.

Moderna's revenue and profit from the coronavirus vaccine

Moderna's success with its COVID-19 vaccine has been driven by its ability to bring the vaccine from the drawing board to commercialization in less than a year. This has resulted in a substantial increase in the company's revenue and profit. However, there have been concerns about Moderna's vaccine distribution, with the company supplying its shots almost exclusively to wealthy nations, keeping poorer countries waiting and paying more.

Despite the decline in global demand for the COVID-19 vaccine as the worst of the pandemic has eased, Moderna continues to expect the U.S. annual COVID-19 market to be 100 million doses. The company is also in discussions about new contracts with customers in Europe, Japan, and the U.S. that could further boost vaccine revenue.

In addition to its COVID-19 vaccine sales, Moderna is expanding its efforts in cancer treatment, partnering with Merck on a cancer vaccine. The company is also developing a combination vaccine to prevent COVID-19 and the flu in one shot, with results expected before the end of 2023.

While Moderna's stock has experienced volatility, with sales and share prices falling at times, the company's overall trajectory has been positive. Analysts project sales to accelerate in the third and fourth quarters of 2024, with expected revenue of $1.5 billion and $2.34 billion, respectively.

The company's 44 programs in development

Moderna's success with its coronavirus vaccine has led to a significant drop in the risk of investing in the company. The company is now very close to becoming a multi-product entity, with two more products expected to enter the market in the next few years. The company has 44 programs in development, and even if only a few of these make it to market, the company could continue to be successful.

Moderna's 44 programs in development include five candidates in phase 2 studies or beyond (excluding those in the coronavirus program). The company has recently begun phase 3 trials for a cytomegalovirus (CMV) vaccine candidate and a respiratory syncytial virus (RSV) vaccine candidate. Both of these could be significant opportunities for the company. CMV is a common virus that can be particularly dangerous for certain individuals, and currently, no CMV vaccine exists. For RSV protection, only an antibody treatment is available.

In addition to these, Moderna is also working on other applications of potential mRNA therapeutics that could help people with cancer, metabolic diseases, and more. The company is partnered with Merck on a cancer vaccine, and the combination of this vaccine with Merck's Keytruda has shown promising results in patients with kidney cancer, bladder cancer, and cutaneous squamous cell carcinoma. They are also testing the cancer vaccine in patients with lung cancer.

Moderna is also developing a 10-year subscription program for an annual COVID-19 booster, and it is already in negotiations with several countries. The company also plans to raise the price of its vaccine once it starts selling to private buyers, such as pharmacies, instead of directly to governments.

Furthermore, Moderna has an extensive pipeline of mRNA medicines in development, which could be used to treat a wide range of diseases and conditions. This includes infectious disease vaccines, latent and public health vaccines, cardiovascular therapeutics, and rare disease intercellular therapeutics.

The potential for Moderna to become a multi-product company

Moderna is a biotechnology company that develops medicines based on messenger ribonucleic acid (mRNA). The company's mRNA technology has proven its safety and efficacy in humans with the success of its coronavirus vaccine, Spikevax®. This has brought in billions of dollars in revenue and profit for the company. Moderna is now very close to becoming a multi-product company, with two more potential products in the pipeline that may be close behind.

The first is a cytomegalovirus (CMV) vaccine candidate, which is currently in phase 3 trials. CMV is a common virus that can be particularly dangerous for certain individuals, and there is currently no vaccine available. The second potential product is a respiratory syncytial virus (RSV) vaccine candidate, which is also in phase 3 trials. RSV is another common virus that can be dangerous, and only an antibody treatment exists for protection. Moderna's RSV vaccine has already been approved by the FDA for use in adults aged 60 and older, and the company plans to launch it in the fall of 2024.

In addition to these two candidates, Moderna has a total of 44 programs in development, with 40 in clinical studies as of 2023. The company is also expanding its efforts in cancer treatment, partnering with Merck on a cancer vaccine that has shown promising results. They have also established an R&D relationship with Immatics, a biopharmaceutical company, to develop successful cancer therapies.

With its successful coronavirus vaccine, two potential new products in late-stage development, and a strong pipeline of 44 programs, Moderna has the potential to become a multi-product company in the near future. This could provide a more stable source of revenue and profit for the company and reduce the risk of investing in the company.

The company's 10-year subscription program

Moderna, an American pharmaceutical and biotechnology company, has been making waves in the stock market since its initial public offering in 2018. The company's success is largely attributed to its coronavirus vaccine, which has brought in billions of dollars in revenue. However, there are concerns about the sustainability of this success as the pandemic wanes. In response, Moderna has developed a 10-year subscription program to ensure the continued sale of its annual booster vaccine. This subscription model is a strategic move to secure long-term demand for their product.

The 10-year subscription program aims to provide an annual booster vaccine to subscribed individuals. This subscription service is currently being negotiated with several countries, ensuring a steady demand for Moderna's coronavirus vaccine. This approach is particularly appealing to countries that want to protect their vulnerable populations from the ongoing threat of the coronavirus. By committing to a long-term subscription, these countries can guarantee access to the vaccine for their citizens.

The subscription model also allows Moderna to project future revenue and profit more accurately. With a set number of subscribers, the company can forecast the demand for its vaccine more reliably, enabling better planning and resource allocation. This stability is advantageous for a company operating in a volatile market, where demand can fluctuate significantly.

Additionally, the 10-year subscription program provides Moderna with an opportunity to diversify its customer base. By selling directly to private buyers, such as pharmacies, the company can increase its profit margins. This strategy is particularly appealing in countries where the vaccine is not fully covered by the government or insurance providers. By charging a higher price to private buyers, Moderna can maximize its revenue and maintain profitability.

The 10-year subscription program is a testament to Moderna's proactive approach to sustaining its success in a dynamic market. By securing long-term demand, diversifying its customer base, and increasing its profit margins, the company is well-positioned to remain a prominent player in the biotechnology industry. This subscription model not only benefits Moderna but also ensures that individuals worldwide have continued access to vital vaccine protection.

Moderna's stock performance since 2019

Moderna's stock performance has been mixed since 2019. The company's initial public offering (IPO) in late 2018 was priced at $23 per share. In 2020, the stock price soared by more than 434%, and it continued to rise in 2021, gaining 143%. However, in 2022 and 2023, Moderna's stock price declined, falling by 29% and nearly 45%, respectively.

Despite the recent setbacks, Moderna has been generating substantial revenue and profits due to its successful coronavirus vaccine. The company's revenue from vaccine sales reached $6.7 billion in 2023, and it achieved a 48% market share for COVID vaccines in the US during the fall of that year.

In addition to its coronavirus vaccine, Moderna has several other promising candidates in its pipeline. It is developing vaccines for cytomegalovirus (CMV) and respiratory syncytial virus (RSV), as well as cancer treatments. These programs have advanced to late-stage development, with some in phase 3 trials. The company is also investing in research and development for several new vaccines, including for HIV and malaria.

However, there are concerns about the sustainability of Moderna's vaccine revenue. As the demand for COVID-19 vaccines declines in the post-pandemic era, the company has paused plans to build a vaccine manufacturing facility in Kenya. There are worries that countries will order fewer vaccine doses if the virus becomes less of a threat.

Overall, Moderna's stock performance since 2019 has been volatile, with significant gains followed by recent declines. The company's success with its coronavirus vaccine and its expanding pipeline of vaccine and treatment candidates show promise, but there are uncertainties about the future demand for its products.

Frequently asked questions